Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sensor measurements

- PMLiVE

Novavax initiates phase 2 combination COVID-19/flu vaccine study

Initial results from the trial are expected towards the middle of the year

- PMLiVE

RQ Bio-discovered antibody enters clinic as part of AstraZeneca COVID-19 study

The trial will evaluate the UK-based biotech’s AZD3152 in combination with cilgavimab

- PMLiVE

Roche’s COVID-19 antibody receives FDA approval for hospitalised adults

The decision makes Actemra the first FDA-approved monoclonal antibody to treat COVID-19

- PMLiVE

CHMP recommends use of Moderna’s Omicron BA.1 booster in children in the EU

The company is also evaluating the use of the vaccine in children aged from six months

- PMLiVE

MHRA set to receive nearly £1m from BEIS’ Regulator’s Pioneer Fund

Funding will aid three projects aiming to harness digital, data and scientific regulatory innovation

- PMLiVE

WHO joins calls for equitable access to healthcare products ahead of future pandemics

The WHO, WIPO and WTO gathered at the Joint Technical Symposium on 16 December

Can Artificial Intelligence Solve the Healthcare Crisis?

Healthcare systems around the world are already struggling to meet the demands of an ageing population, the rising incidence of chronic diseases, escalating healthcare costs and a deficit of healthcare...

Page & Page and Partners

- PMLiVE

WHO member states commit to producing a pandemic accord in 2023

The ‘zero draft’ will be a legally binding agreement, part of the WHO Constitution

- PMLiVE

UK Government launches new taskforce to help NHS tackle COVID-19 backlogs

Experts will focus on how the NHS can utilise existing capacity in the independent sector

- PMLiVE

FDA approves updated COVID-19 boosters for children aged from six months

The Moderna and Pfizer/BioNTech boosters both target the BA.4/BA.5 omicron subvariants

- PMLiVE

EMA’s emergency task force backs bivalent COVID-19 vaccines for primary vaccination

National authorities may decide to use the vaccines in their primary vaccination campaigns

- PMLiVE

Pfizer and Clear Creek Bio partner on COVID-19 antiviral research programme

The companies will identify a papain-like protease candidate to progress into the clinic

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links